A recent study has shown that administration of FGF19 causes skeletal muscle hypertrophy, by stimulating the phosphorylation of ERK1/2 and P70S6K1, and ameliorates obesity-induced skeletal muscle atrophy in mice (37). Here, FGF19 is linked to obesity disorder.